Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;48(6):741-744.
doi: 10.1111/cea.13120. Epub 2018 Mar 23.

Alum-adjuvanted allergoids induce functional IgE-blocking antibodies

M Reithofer  1 , S L Böll  1 , C Kitzmüller  1 , F Horak  2 , M Sotoudeh  2 , B Bohle  1 , B Jahn-Schmid  1
Affiliations

Alum-adjuvanted allergoids induce functional IgE-blocking antibodies

M Reithofer et al. Clin Exp Allergy. 2018 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preseasonal GP‐AIT with allergoid. The schedule of treatment and blood sampling is shown (A). Ex vivo basophil reactivity of 10 patients to GP‐extract before, after 4 and 12 months of treatment is shown (B). Grey bars represent means (Kruskal‐Wallis plus Dunn's post hoc test; *P ≤ .05; **P ≤ .01)
Figure 2
Figure 2
Allergen‐specific Ig‐response and IgE‐blocking capacity in patients undergoing AIT with allergoid. IgE, IgG, IgG1 and IgG4 levels were assessed by ELISA using GP‐extract (A), recombinant Phl p 1 (B) or recombinant Phl p 5 (C) for coating. Blocking capacity of sera was determined by blocking IgE‐allergen complex formation (FAB assay) (D) or by blocking the activation of basophils with GP‐extract from an allogeneic GP‐allergic individual (BAT assay) (E). Per cent inhibition as compared to pretreatment levels is shown. Grey bars represent means (Kruskal‐Wallis plus Dunn's post hoc test; *P ≤ .05; **P ≤ .01; ***P ≤ .001)
See this image and copyright information in PMC

References

    1. Calderon MA, Alves B, Jakobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis (Protocol). Cochran Database Syst Rev. 2007;1: CD001936. - PMC - PubMed
    1. Brehler R, Kahlert H, Thum‐Oltmer S. Immunological features and their impact on clinical efficacy and safety, exemplary for the allergoids Allergovit®, Acaroid®, and a folding variant of the recombinant birch pollen major allergen Bet v 1. Allergo J. 2010;19:477‐484.
    1. Shamji MH, Ljorring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67:217‐226. - PubMed
    1. Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double‐blind placebo‐controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy. 2008;38:1290‐1301. - PubMed
    1. Özdemir SK, Sin AS, Güloglu D, Ikinciogullari A, Genctürk Z, Misirigil Z. Short‐term pre‐seasonal immunotherapy: is early clinical efficacy related to the basophil response? Int Arch Allergy Immunol. 2014;164:237‐245. - PubMed

Publication types

LinkOut - more resources